Friday, Candel Therapeutics Inc ( CADL ) shares are trading higher on heavy volume with a session volume of 7.89 million versus the average volume of 2.37 million, as per data from Benzinga Pro.

Candel Therapeutics ( CADL ) shares are trading higher on continued strength after the company announced interim data from the randomized phase 2 clinical trial of CAN-2409 in non-metastatic pancreatic cancer on Thursday.

Prolonged and sustained survival was observed after experimental treatment with CAN-2409 in patients with borderline resectable pancreatic ductal adenocarcinoma (n=13).

The estimated median overall survival was 28.8 months in the CAN-2409 group versus only 12.5 months in the control group.

 At 24 months, a survival rate of 71.4% was observed in CAN-2409 treated patients after SoC chemoradiation and before surgery, versus only 16.7% in the control group. 

 At 36 months, a survival rate of 47.6% was estimated in patients who received CAN-2409, together with SoC chemoradiation before surgery, versus only 16.7% in the control group.

On Monday, the company announced the presentation of updated data from an ongoing phase 1b trial of its herpes simplex virus-1 (HSV-1) replication-competent viral immunotherapy candidate, CAN-3110, in patients with recurrent high-grade glioma (rHGG) recurred after standard of care (SoC) treatment. 

The investigators observed a nearly doubling of the expected median overall survival (mOS) after a single CAN-3110 injection, achieving a mOS of ~12 months, compared to historical reports of less than 6 to 9 months in this therapy-resistant condition. 

Candel Therapeutics ( CADL ) CEO Paul Peter Tak, MD featured on Benzinga’s premarket prep show to talk about the latest developments in the company.

Price Action: CADL shares are up 15.20% at $7.37 during the premarket session on the last check Friday.